Michael Benatar1, Lanyu Zhang2, Lily Wang2, Volkan Granit2, Jeffrey Statland2, Richard Barohn2, Andrea Swenson2, John Ravits2, Carlayne Jackson2, Ted M Burns2, Jaya Trivedi2, Erik P Pioro2, James Caress2, Jonathan Katz2, Jacob L McCauley2, Rosa Rademakers2, Andrea Malaspina2, Lyle W Ostrow2, Joanne Wuu. 1. From Miller School of Medicine (M.B., L.Z., L.W., V.G., J.W.), University of Miami, FL; Kansas University Medical Center (J.S., R.B.), Kansas City; University of Iowa (A.S.), Iowa City; University of California San Diego (J.R.); University of Texas Health Science Center San Antonio (C.J.); University of Virginia (T.M.B.), Charlottesville; UT Southwestern Medical Center (J.T.), Dallas, TX; Cleveland Clinic (E.P.P.), OH; Wake Forest School of Medicine (J.C.), Winston-Salem, NC; California Pacific Medical Center (J.K.), San Francisco; John P Hussman Institute for Human Genomics (J.L.M.), Miami; Mayo Clinic Jacksonville (R.R.), FL; Blizard Institute (A.M.), Queen Mary University of London, UK; and Johns Hopkins University (L.W.O.), Baltimore, MD. mbenatar@med.miami.edu jwuu@med.miami.edu. 2. From Miller School of Medicine (M.B., L.Z., L.W., V.G., J.W.), University of Miami, FL; Kansas University Medical Center (J.S., R.B.), Kansas City; University of Iowa (A.S.), Iowa City; University of California San Diego (J.R.); University of Texas Health Science Center San Antonio (C.J.); University of Virginia (T.M.B.), Charlottesville; UT Southwestern Medical Center (J.T.), Dallas, TX; Cleveland Clinic (E.P.P.), OH; Wake Forest School of Medicine (J.C.), Winston-Salem, NC; California Pacific Medical Center (J.K.), San Francisco; John P Hussman Institute for Human Genomics (J.L.M.), Miami; Mayo Clinic Jacksonville (R.R.), FL; Blizard Institute (A.M.), Queen Mary University of London, UK; and Johns Hopkins University (L.W.O.), Baltimore, MD.
Abstract
OBJECTIVE: To identify preferred neurofilament assays and clinically validate serum neurofilament light (NfL) and phosphorylated neurofilament heavy (pNfH) as prognostic and potential pharmacodynamic biomarkers relevant to amyotrophic lateral sclerosis (ALS) therapy development. METHODS: In this prospective, multicenter, longitudinal observational study of patients with ALS (n = 229), primary lateral sclerosis (n = 20), and progressive muscular atrophy (n = 11), biological specimens were collected, processed, and stored according to strict standard operating procedures (SOPs). Neurofilament assays were performed in a blinded manner by independent contract research organizations. RESULTS: For serum NfL and pNfH measured using the Simoa assay, there were no missing data (i.e., technical replicates below the lower limit of detection were not encountered). For the Iron Horse and Euroimmun pNfH assays, such missingness was encountered in ∼4% and ∼10% of serum samples, respectively. Mean coefficients of variation for NfL in serum and CSF were both ∼3%. Mean coefficients of variation for pNfH in serum and CSF were ∼4%-5% and ∼2%-3%, respectively, in all assays. Baseline serum NfL concentration, but not pNfH, predicted the future Revised ALS Functional Rating Scale (ALSFRS-R) slope and survival. Incorporation of baseline serum NfL into mixed effects models of ALSFRS-R slopes yields an estimated sample size saving of ∼8%. Depending on the method used to estimate effect size, use of serum NfL (and perhaps pNfH) as pharmacodynamic biomarkers, instead of the ALSFRS-R slope, yields significantly larger sample size savings. CONCLUSIONS: Serum NfL may be considered a clinically validated prognostic biomarker for ALS. Serum NfL (and perhaps pNfH), quantified using the Simoa assay, has potential utility as a pharmacodynamic biomarker of treatment effect.
OBJECTIVE: To identify preferred neurofilament assays and clinically validate serum neurofilament light (NfL) and phosphorylated neurofilament heavy (pNfH) as prognostic and potential pharmacodynamic biomarkers relevant to amyotrophic lateral sclerosis (ALS) therapy development. METHODS: In this prospective, multicenter, longitudinal observational study of patients with ALS (n = 229), primary lateral sclerosis (n = 20), and progressive muscular atrophy (n = 11), biological specimens were collected, processed, and stored according to strict standard operating procedures (SOPs). Neurofilament assays were performed in a blinded manner by independent contract research organizations. RESULTS: For serum NfL and pNfH measured using the Simoa assay, there were no missing data (i.e., technical replicates below the lower limit of detection were not encountered). For the Iron Horse and Euroimmun pNfH assays, such missingness was encountered in ∼4% and ∼10% of serum samples, respectively. Mean coefficients of variation for NfL in serum and CSF were both ∼3%. Mean coefficients of variation for pNfH in serum and CSF were ∼4%-5% and ∼2%-3%, respectively, in all assays. Baseline serum NfL concentration, but not pNfH, predicted the future Revised ALS Functional Rating Scale (ALSFRS-R) slope and survival. Incorporation of baseline serum NfL into mixed effects models of ALSFRS-R slopes yields an estimated sample size saving of ∼8%. Depending on the method used to estimate effect size, use of serum NfL (and perhaps pNfH) as pharmacodynamic biomarkers, instead of the ALSFRS-R slope, yields significantly larger sample size savings. CONCLUSIONS: Serum NfL may be considered a clinically validated prognostic biomarker for ALS. Serum NfL (and perhaps pNfH), quantified using the Simoa assay, has potential utility as a pharmacodynamic biomarker of treatment effect.
Authors: F Kimura; C Fujimura; S Ishida; H Nakajima; D Furutama; H Uehara; K Shinoda; M Sugino; T Hanafusa Journal: Neurology Date: 2006-01-24 Impact factor: 9.910
Authors: Patrick Oeckl; Claude Jardel; François Salachas; Foudil Lamari; Peter M Andersen; Robert Bowser; Mamede de Carvalho; Júlia Costa; Philip van Damme; Elizabeth Gray; Julian Grosskreutz; María Hernández-Barral; Sanna-Kaisa Herukka; André Huss; Andreas Jeromin; Janine Kirby; Magdalena Kuzma-Kozakiewicz; Maria Del Mar Amador; Jesús S Mora; Claudia Morelli; Petra Muckova; Susanne Petri; Koen Poesen; Heidrun Rhode; Anna-Karin Rikardsson; Wim Robberecht; Ana I Rodríguez Mahillo; Pamela Shaw; Vincenzo Silani; Petra Steinacker; Martin R Turner; Erdem Tüzün; Berrak Yetimler; Albert C Ludolph; Markus Otto Journal: Amyotroph Lateral Scler Frontotemporal Degener Date: 2016-04-11 Impact factor: 4.092
Authors: Petra Steinacker; André Huss; Benjamin Mayer; Torsten Grehl; Julian Grosskreutz; Guntram Borck; Jens Kuhle; Dorothée Lulé; Thomas Meyer; Patrick Oeckl; Susanne Petri; Jochen Weishaupt; Albert C Ludolph; Markus Otto Journal: Amyotroph Lateral Scler Frontotemporal Degener Date: 2016-11-05 Impact factor: 4.092
Authors: Federico Verde; Petra Steinacker; Jochen H Weishaupt; Jan Kassubek; Patrick Oeckl; Steffen Halbgebauer; Hayrettin Tumani; Christine A F von Arnim; Johannes Dorst; Emily Feneberg; Benjamin Mayer; Hans-Peter Müller; Martin Gorges; Angela Rosenbohm; Alexander E Volk; Vincenzo Silani; Albert C Ludolph; Markus Otto Journal: J Neurol Neurosurg Psychiatry Date: 2018-10-11 Impact factor: 10.154
Authors: Ching-Hua Lu; Corrie Macdonald-Wallis; Elizabeth Gray; Neil Pearce; Axel Petzold; Niklas Norgren; Gavin Giovannoni; Pietro Fratta; Katie Sidle; Mark Fish; Richard Orrell; Robin Howard; Kevin Talbot; Linda Greensmith; Jens Kuhle; Martin R Turner; Andrea Malaspina Journal: Neurology Date: 2015-05-01 Impact factor: 9.910
Authors: Basil T Darras; Thomas O Crawford; Richard S Finkel; Eugenio Mercuri; Darryl C De Vivo; Maryam Oskoui; Eduardo F Tizzano; Monique M Ryan; Francesco Muntoni; Guolin Zhao; John Staropoli; Alexander McCampbell; Marco Petrillo; Christopher Stebbins; Stephanie Fradette; Wildon Farwell; Charlotte J Sumner Journal: Ann Clin Transl Neurol Date: 2019-04-17 Impact factor: 4.511
Authors: Iddo Magen; Nancy Sarah Yacovzada; Eran Yanowski; Anna Coenen-Stass; Julian Grosskreutz; Ching-Hua Lu; Linda Greensmith; Andrea Malaspina; Pietro Fratta; Eran Hornstein Journal: Nat Neurosci Date: 2021-10-28 Impact factor: 24.884
Authors: James Berry; Benjamin Brooks; Angela Genge; Terry Heiman-Patterson; Stanley Appel; Michael Benatar; Robert Bowser; Merit Cudkowicz; Clifton Gooch; Jeremy Shefner; Jurjen Westra; Wendy Agnese; Charlotte Merrill; Sally Nelson; Stephen Apple Journal: Neurol Clin Pract Date: 2021-08
Authors: Eva Buck; Patrick Oeckl; Veselin Grozdanov; Verena Bopp; Julia K Kühlwein; Wolfgang P Ruf; Diana Wiesner; Francesco Roselli; Jochen H Weishaupt; Albert C Ludolph; Markus Otto; Karin M Danzer Journal: Acta Neuropathol Date: 2022-05-18 Impact factor: 15.887
Authors: Shreyasee Das; Nele Dewit; Dirk Jacobs; Yolande A L Pijnenburg; Sjors G J G In 't Veld; Salomé Coppens; Milena Quaglia; Christophe Hirtz; Charlotte E Teunissen; Eugeen Vanmechelen Journal: Int J Mol Sci Date: 2022-06-29 Impact factor: 6.208